# **Special Issue**

# The Emerging Field of Critical Care Psychiatry: Pharmacologic Treatment from ICU to Post-ICU Recovery

# Message from the Guest Editors

Critical care psychiatry is an emerging field focused on the recognition and management of neuropsychiatric syndromes that occur during and after critical illness. Patients in the ICU (intensive care unit) are at high risk for developing conditions such as delirium, insomnia, depressive episodes, anxiety, and trauma-related disorders—yet psychiatric care in this setting remains fragmented and underdeveloped.

This Special Issue of Pharmaceuticals seeks to advance the field by highlighting pharmacologic strategies for managing acute and post-ICU psychiatric disorders and syndromes. We welcome original research, reviews, and case reports examining the use of pharmacologic agents to manage delirium, sleep disturbances, depression, anxiety, and trauma-related conditions in ICU patients and subsequent sequelae in survivors. Submissions that address both inpatient and outpatient care across the critical illness continuum are encouraged. We especially invite interdisciplinary contributions from psychiatry, critical care, pharmacy, internal medicine, geriatrics, and other specialties routinely involved in the acute and post-acute critical care of neuropsychiatric conditions.

### **Guest Editors**

Dr. Shixie Jiang

Dr. Matthew Gunther

Dr. Jose R. Maldonado

# Deadline for manuscript submissions

28 February 2026



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/248485

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





# **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



# **About the Journal**

# Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

### Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

# **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

